The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma

Published:2021-02-02 Issue:2 Volume:16 Page:153-163
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Liu Lin,Qin Shukui^ORCID,Zhang Yu

Funder

the National Key R & D Program of China

the CSCO Cancer Research Fund

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11523-020-00787-x.pdf

Reference34 articles.

1. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389(10088):2492–502. https://doi.org/10.1016/S0140-6736(17)31046-2.

2. Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. CheckMate 459: a randomized, multi-center phase 3 study of Nivolumab (Nivolumab) vs Sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma. Ann Oncol. 2019;30(Suppl 5):V874–5. https://doi.org/10.1093/annonc/mdz394.029.

3. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S , Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19(7): 940–52. https://doi.org/10.1016/S1470-2045(18)30351-6.

4. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020; 38 (3):193–202. https://doi.org/10.1200/JCO.19.01307.

5. Gnoni A, Santini D, Scartozzi M, Russo A, Licchetta A, Palmieri V, et al. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? Expert Opin Ther Targets. 2015; 19(12):1623–35. https://doi.org/10.1517/14728222.2015.1071354.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma;BMC Cancer;2022-08-09

2. Immune-Related lncRNA Pairs Clinical Prognosis Model Construction for Hepatocellular Carcinoma;International Journal of General Medicine;2022-02

3. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting;Journal of Clinical Medicine;2021-07-21

4. The value of contrast-enhanced ultrasound in predicting postoperative recurrence of hepatocellular carcinoma;Medicine;2021-06-04

5. CXCL5 Has Potential to Be a Marker for Hepatocellular Carcinoma Prognosis and Was Correlating With Immune Infiltrates;Frontiers in Oncology;2021-03-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3